Drug Profile


Alternative Names: CAB 2001; Fiblast Spray; KCB-1; KCB-1B; KCB-1D

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scios
  • Developer Kaken Pharmaceutical; Olympus Corporation; Scios
  • Class Fibroblast growth factors; Peptide fragments; Vascular disorder therapies
  • Mechanism of Action Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Skin ulcer
  • Preregistration Periodontitis
  • Discontinued Coronary disorders; Diabetic foot ulcer; Fracture; Peripheral vascular disorders; Postmenopausal osteoporosis; Stroke

Most Recent Events

  • 31 Dec 2014 Trafermin is still in phase III trials for Periodontitis in Japan (Topical, gel)
  • 31 Dec 2014 Discontinued - Phase-II for Diabetic foot ulcer in Japan (Topical, gel)
  • 31 Dec 2014 Discontinued - Phase-II for Fracture in Japan (Topical, gel)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top